LMY-920
LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
What will happen during the trial?
In this open label, dose escalation study, up to four dose levels of autologous BAFF ligand CAR-T cells (LMY-920) will be evaluated for treatment relapsed and refractory myeloma. BAFF receptor family includes B-cell activating factor receptor (BR3), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design. The primary goal of this study is to determine recommended phase II dose of human LMY-920 in patients with relapsed or refractory myeloma.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Luminary Therapeutics
- Collaborators
- Cleveland Clinic - Taussig Cancer Center, Case Western Reserve University
- Tags
- CAR T Cell, B-Cell Activating Factor (BAFF)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1313
- NCT Identifier
- NCT05546723
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.